

PRODUCT INFORMATION



Melagatran

Item No. 9002300

CAS Registry No.: 159776-70-2

Formal Name: N-[(1R)-2-[(2S)-2-[[[4-(aminoiminomethyl)phenyl]methyl]amino]carbonyl]-1-azetidiny]-1-cyclohexyl-2-oxoethyl]-glycine

MF: $C_{22}H_{31}N_5O_4$


FW: 429.5

Purity: $\geq 90\%$

Supplied as: A solid

Storage: -20°C

Stability: ≥ 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Melagatran is supplied as a solid. A stock solution may be made by dissolving the melagatran in the solvent of choice, which should be purged with an inert gas. Melagatran is sparingly soluble (1-10 mg/ml) in DMSO.

Description

Melagatran is an inhibitor of thrombin ($K_i = 0.002 \mu\text{M}$) and an active metabolite of the prodrug ximelagatran (Item No. 16862).¹ It is selective for thrombin over a variety of serine proteases (K_i s = 0.6-10.2 μM) but also inhibits trypsin ($K_i = 0.004 \mu\text{M}$). Melagatran inhibits thrombin-induced aggregation of isolated washed human platelets ($\text{IC}_{50} = 1.9 \text{ nM}$). It decreases the dry weight of thrombi in rats ($\text{ED}_{50} = 16 \mu\text{g/kg}$).² Melagatran increases total bleeding time and blood loss in rats (ID_{50} s = 300 and 6.8 $\mu\text{g/kg}$, respectively).³ Melagatran (5 $\mu\text{mol/kg}$ per hour), alone or in combination with tissue plasminogen activator (tPA), reduces brain infarct volume and increases blood reperfusion in a rat model of ischemia-induced traumatic brain injury (TBI).⁴

References

1. Gustafsson, D., Antonsson, T., Bylund, R., *et al.* Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. *Thromb. Haemost.* **79(1)**, 110-118 (1998).
2. Eriksson, B.I., Carlsson, S., Halvarsson, M., *et al.* Antithrombotic effect of two low molecular weight thrombin inhibitors and a low-molecular weight heparin in a caval vein thrombosis model in the rat. *Thromb. Haemost.* **78(5)**, 1404-1407 (1997).
3. Elg, M., Gustafsson, D., and Carlsson, S. Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat. *Thromb. Res.* **94(3)**, 187-197 (1999).
4. Wang, C.X., Ding, X., and Shuaib, A. Treatment with melagatran alone or in combination with thrombolytic therapy reduced ischemic brain injury. *Exp. Neurol.* **213(1)**, 171-175 (2008).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 05/14/2025

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM